SynthesisJournal of robotic surgery2026
Robotic hepatectomy for benign liver disease: single-centre consecutive series and meta-analysis comparing minimally invasive and open approaches.
Synthesis in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign hepatic disease carries a distinctive ethical imperative to minimize perioperative morbidity in patients who might otherwise live asymptomatic lives. Minimally invasive approaches reduce pain, hospitalization, and recovery time, but laparoscopic resection of anatomically challenging posterosuperior segments remains technically demanding. Robotic hepatectomy may overcome these limitations. This study evaluates the safety, feasibility, learning curve, and comparative effectiveness of robotic hepatectomy in benign disease. We retrospectively analyzed a consecutive single-surgeon series of 62 robotic hepatectomies for benign disease, including a learning-curve analysis, and performed a parallel meta-analysis of 7 comparative studies stratified by surgical approach and lesion complexity. Robotic resection demonstrated excellent safety (1.6% major complication rate, 0% 90-day mortality, 0% readmissions) and reproducibility. The IWATE score reliably stratified cases and predicted operative duration. In the literature, robotic and laparoscopic resection showed comparable operative time, blood loss, and length of stay, with only a modestly longer robotic operative time in isolated resections (SMD + 0.52, p = 0.0046). Compared with open surgery, the robotic approach achieved significantly lower intraoperative blood loss (SMD - 0.94, p < 0.0001) and a shorter hospital stay (SMD - 1.32, p = 0.0253), with comparable operative time. The blood-loss advantage over open surgery was confirmed in strictly isolated benign resections (SMD - 0.71, p = 0.0004; I² = 0%). Robotic hepatectomy is safe, reproducible, and demonstrates clear learning curve plateau in benign disease and a stepping-stone strategy for malignant liver diseases. Robotic resection reliably accesses posterosuperior segments with low conversion rates, making it an attractive minimally invasive alternative that extends laparoscopic reach. In benign disease, where morbidity minimization and rapid recovery are paramount, robotic surgery offers a compelling new option. Future prospective, multicenter, randomized studies are needed for cost-effectiveness and quality-of-life analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.